pLX401-INK4A Citations (2)

Originally described in: MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM Cancer Res. 2019 Feb 12. pii: 0008-5472.CAN-18-3066. doi: 10.1158/0008-5472.CAN-18-3066. PubMed Journal

---

Articles Citing pLX401-INK4A

Articles
p16(INK4A)-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Leone JP, Long HW, Brown MA, Winer EP, Dillon DAR, Lin NU, Zhao JJ. Nat Commun. 2022 Mar 18;13(1):1473. doi: 10.1038/s41467-022-29081-2. PubMed
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Braso-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Odena A, Sanchez-Guixe M, Capelan M, Azaro A, Bruna A, Rodriguez O, Guzman M, Grueso J, Viaplana C, Hernandez J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, Garcia-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.